Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY – Get Free Report) saw a large decrease in short interest in December. As of December 15th, there was short interest totaling 18,708 shares, a decrease of 32.6% from the November 30th total of 27,751 shares. Based on an average daily volume of 54,765 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 54,765 shares, the short-interest ratio is presently 0.3 days.
Sinopharm Group Price Performance
Shares of SHTDY opened at $12.42 on Wednesday. Sinopharm Group has a 52-week low of $10.72 and a 52-week high of $14.13. The business’s 50 day moving average price is $12.86 and its two-hundred day moving average price is $12.30.
About Sinopharm Group
Sinopharm Group Co, Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co, Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.
In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions.
Featured Stories
- Five stocks we like better than Sinopharm Group
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
- ALERT: Drop these 5 stocks before January 2026!
- [No Brainer Gold Play]: “Show me a better investment.”
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
